The Future of COVID-19: What Is Next in the Drug Pipeline
Value in Health
; 26(6 Supplement):S39, 2023.
Article
Dans Anglais
| EMBASE | ID: covidwho-20233799
ABSTRACT
Objectives:
Development of new and repurposed medicines in response to the COVID-19 pandemic has occurred at an unprecedented rate, resulting in a dynamic pipeline marked by significant challenges and successes. This analysis provides an overview of the vaccines and therapies undergoing clinical evaluation or with recent approval for the treatment and prevention of COVID-19 in global markets. Method(s) For this analysis, COVID-19 pipeline medicines are defined in three categories vaccines, new treatments and repurposed medicines. GlobalData is the primary data source for this study, in addition to online databases from Health Canada, the US FDA, and the EMA. International markets examined include the US and geographic Europe (excluding Russia and Turkey). Result(s) As of November 2022, the global pipeline contained over 600 therapies and vaccines undergoing Phase I, II, III clinical trials or pre-registration for the prevention and treatment of COVID-19. Preventive and repurposed medicines include antivirals, immunoglobulins, monoclonal antibodies, cellular therapies, and convalescent plasma. In Canada, twelve medicines, including six vaccines, have been approved for COVID-19. The number of global approvals is greater, with approximately 9 vaccines on the market in OECD countries. In addition to pre-exposure preventative therapies, manufacturers are also developing COVID-19 drugs to be used as prophylactic therapy. The analysis identifies new oral antiviral treatments and preventative therapies in the pipeline and under review in various jurisdictions globally. Conclusion(s) This research provides a clearer picture of the characteristics and evolution of the market for new and emerging COVID-19 medicines, which will help policy-makers and other stakeholders understand and anticipate the unique pressures of the COVID-19 pandemic.Copyright © 2023
antiviral therapy; Canada; cell therapy; clinical evaluation; conference abstract; controlled study; coronavirus disease 2019; data source; drug therapy; Europe; Food and Drug Administration; Health Canada; human; Organisation for Economic Co-operation and Development; pandemic; pipeline; prevention; prophylaxis; Russian Federation; Turkey (republic); antivirus agent; convalescent plasma; endogenous compound; immunoglobulin; monoclonal antibody; vaccine
Texte intégral:
Disponible
Collection:
Bases de données des oragnisations internationales
Base de données:
EMBASE
Type d'étude:
Études expérimentales
/
Étude pronostique
Les sujets:
Vaccins
langue:
Anglais
Revue:
Value in Health
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS